IRIS

LA MONICA, Silvia

LA MONICA, Silvia  

Dipartimento di Medicina e Chirurgia  

Mostra records
Risultati 1 - 20 di 106 (tempo di esecuzione: 0.02 secondi).
Titolo Data di pubblicazione Autore(i) File
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 1-gen-2018 Morgillo, F.; Corte, C. M. Della; Alfieri, R.; Petronini, P.; La Monica, S.; Papaccio, F.; Ciardiello, F.
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 1-gen-2023 Adorni, Maria Pia; Galetti, Maricla; La Monica, Silvia; Incerti, Matteo; Ruffoni, Alessandro; Elviri, Lisa; Zanotti, Ilaria; Papotti, Bianca; Cavallo, Delia; Alfieri, Roberta; Petronini, Pier Giorgio; Bernini, Franco
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 1-gen-2021 Ferlenghi, F; Scalvini, L; Vacondio, F; Castelli, R; Bozza, N; Marseglia, G; Rivara, S; Lodola, A; La Monica, S; Minari, R; Petronini, Pg; Alfieri, R; Tiseo, M; Mor, M.
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 1-gen-2019 La Monica, S.; Minari, R.; Cretella, D.; Bonelli, M.; Fumarola, C.; Cavazzoni, A.; Galetti, M.; Digiacomo, G.; Riccardi, F.; Petronini, P. G.; Tiseo, M.; Alfieri, R.
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 1-gen-2021 Minari, R.; Leonetti, A.; Gnetti, L.; Zielli, T.; Ventura, L.; Bottarelli, L.; Lagrasta, C.; la Monica, S.; Petronini, P. G.; Alfieri, R.; Tiseo, M.
Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage 1-gen-2005 Fumarola, C; La Monica, S; Guidotti, Gg
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 1-gen-2010 Fumarola, Claudia; Bonelli, Mara; K., Airoud; Alfieri, Roberta; Cavazzoni, Andrea; Galetti, Maricla; LA MONICA, Silvia; D., Generali; Petronini, Pier Giorgio
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 1-gen-2008 Bonelli, Mara; Fumarola, Claudia; Alfieri, Roberta; Gatti, Rita; Belletti, Silvana; LA MONICA, Silvia; Galetti, M; Cavazzoni, Andrea; Frazzi, A; Bottini, A; Bergamini, L; Lynch, M; Harris, Al; Fox, Sb; Generali, Dg
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 1-gen-2008 Bonelli, Mara; Fumarola, Claudia; Alfieri, Roberta; LA MONICA, Silvia; Cavazzoni, Andrea; Galetti, M; Gatti, Rita; Belletti, Silvana; Bottini, A; Generali, D; Petronini, Pier Giorgio
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 1-gen-2018 Della Corte, Carminia Maria; Ciaramella, Vincenza; Cardone, Claudia; La Monica, Silvia; Alfieri, Roberta; Petronini, Pier Giorgio; Malapelle, Umberto; Vigliar, Elena; Pepe, Francesco; Troncone, Giancarlo; Castellone, Maria Domenica; Troiani, Teresa; Martinelli, Erika; Ciardiello, Fortunato; Morgillo, Floriana
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 1-gen-2002 Rizzoli, Vittorio; Sammarelli, G.; Colla, S; Lazzaretti, M.; LA MONICA, S.; Roti, Giovanni; Hojden, M; Bonomini, S.; Sala, Roberto; Mangoni, L.; Genestretti, G.; Fattori, Pp; Giuliani, N.
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 1-gen-2002 Rizzoli, V.; Sammarelli, Gabriella; Colla, S; Lazzaretti, M.; LA MONICA, S.; Roti, Giovanni; Hojden, M; Bonomini, S.; Sala, Roberto; Mangoni, L.; Genestretti, G.
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 1-gen-2002 Rizzoli, V.; Sammarelli, G.; Colla, S; Lazzaretti, M.; LA MONICA, S.; Roti, Giovanni; Hojden, M; Bonomini, S.; Sala, Roberto; Mangoni, L.; Genestretti, G.; Fattori, Pp; Giuliani, Nicola
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 1-gen-2022 Terenziani, Rita; Galetti, Maricla; La Monica, Silvia; Fumarola, Claudia; Zoppi, Silvia; Alfieri, Roberta; Digiacomo, Graziana; Cavazzoni, Andrea; Cavallo, Delia; Corradi, Massimo; Tiseo, Marcello; Petronini, Pier Giorgio; Bonelli, Mara
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 1-gen-2023 La Monica, S.; Galetti, M.; Alfieri, R.; Cavazzoni, A.; Fumarola, C.; De Forni, D.; Lori, F.; Petronini, P. G.; Bonelli, M.
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 1-gen-2022 Digiacomo, Graziana; Fumarola, Claudia; La Monica, Silvia; Bonelli, Mara; Cavazzoni, Andrea; Galetti, Maricla; Terenziani, Rita; Eltayeb, Kamal; Volta, Francesco; Zoppi, Silvia; Bertolini, Patrizia; Missale, Gabriele; Alfieri, Roberta; Petronini, Pier Giorgio
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 1-gen-2019 Cretella, D; La Monica, S; Minari, R; Cavazzoni, A; Galetti, M; Petronini, P. G.; Tiseo, M; Alfieri, R.
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 1-gen-2005 Fumarola, Claudia; LA MONICA, Silvia; Alfieri, Roberta; Borra, Elena; Guidotti, G. G.
Characterization of gefitinib uptake in NSCLC cell lines 1-gen-2009 M. Galetti M., ; Alfieri, Roberta; Bonelli, Mara; Cavazzoni, Andrea; Fumarola, Claudia; LA MONICA, Silvia; Tiseo, M.; Ardizzoni, Andrea; Petronini, Pier Giorgio
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 1-gen-2020 Rebuzzi, Sara Elena; Alfieri, Roberta; La Monica, Silvia; Minari, Roberta; Petronini, Pier Giorgio; Tiseo, Marcello